CN116115705A - 一种治疗心肌梗塞的中药组合物 - Google Patents
一种治疗心肌梗塞的中药组合物 Download PDFInfo
- Publication number
- CN116115705A CN116115705A CN202110531026.9A CN202110531026A CN116115705A CN 116115705 A CN116115705 A CN 116115705A CN 202110531026 A CN202110531026 A CN 202110531026A CN 116115705 A CN116115705 A CN 116115705A
- Authority
- CN
- China
- Prior art keywords
- parts
- myocardial infarction
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 235000001361 Styrax officinalis Nutrition 0.000 claims abstract description 7
- 235000019382 gum benzoic Nutrition 0.000 claims abstract description 7
- 241001407408 Berberis fortunei Species 0.000 claims abstract description 6
- 244000308495 Potentilla anserina Species 0.000 claims abstract description 6
- 235000016594 Potentilla anserina Nutrition 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000009910 sargent gloryvine Substances 0.000 claims abstract description 5
- 241000522190 Desmodium Species 0.000 claims abstract description 3
- 241000244269 Peucedanum Species 0.000 claims abstract description 3
- 241001060310 Styracaceae Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 244000227573 Desmodium styracifolium Species 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 244000303379 Styrax officinalis Species 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 description 22
- 230000002107 myocardial effect Effects 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 206010042772 syncope Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 241000010428 Alpinia katsumadae Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241001441970 Anserinae Species 0.000 description 1
- 241001083847 Berberis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000001652 xuan cao Nutrition 0.000 description 1
- 244000100739 xuan cao Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗心肌梗塞中药组合物，是由下列重量份的原料药组成：苏合香0.5～1份；猪牙皂1～1.5份；前胡4.5～9份；十大功劳、大血藤、10～20份;刺五加、蕨麻、广金钱草15～30份。本发明具有治疗效果显著、治疗周期短、无毒副作用等特点。
Description
技术领域
本发明属于中药技术领域，尤其是涉及一种治疗心肌梗塞的中药组合物。
背景技术
心肌梗塞是冠状动脉闭塞，血流中断，使部分心肌因严重的持久性缺血而发生局部坏死。
急性心肌梗塞是冠状动脉急性、持续性缺血缺氧所引起的心肌坏死。
临床上多有剧烈而持久的胸骨后疼痛，休息及硝酸酯类药物不能完全缓解，伴有血清心肌酶活性增高及进行性心电图变化，可并发心律失常、休克或心力衰竭，常可危及生命。
西医见效快，但是，容易复发，治标不治本。
发明内容
本发明的目的在于改进已有技术的不足而提供一种心肌梗塞的中药组合物，具有治疗效果显著、治疗周期短、无毒副作用等特点。
本病属于中医“真心痛”、“厥心痛”等病的范畴。
厥心痛指邪犯心包或诸脏之邪犯心之支脉所致之心痛。《医学入门》卷五：“厥心痛，因内外邪犯心包络，或他脏邪犯心之支脉。谓之厥者，诸痛皆少阴、厥阴气逆上冲，又痛极则发厥也。新者身既受寒，后又伤冷，郁遏元阳，宜草豆蔻丸、鸡舌香散温散之，或神保丸温利之……”
《难经·第六十难》：“其五脏相干，名厥心痛。”杨玄操注：“诸经络皆属于心，若一经有病，其脉逆行，逆则乘心，乘心则心痛，故曰厥心痛。”
心肌梗死之血脉闭阻，多为痰瘀交阻、痹阻心脉。表现为阴虚热灼肺阴成痰而为阴虚血瘀挟痰浊，或阳虚水气不化，聚而上泛而为阳虚血瘀夹痰浊。治疗心肌梗死应活血化瘀、补气化浊。
基于上述理论，本发明的技术方案是：一种内服用于治疗心肌梗塞的中药，由下列重量份的原料药组成：苏合香0.5～1份；猪牙皂1～1.5份；前胡4.5～9份；十大功劳、大血藤、10～20份;刺五加、蕨麻、广金钱草15～30份。
在一个优选的实施方案中，所述治疗心肌梗塞的中药组合物由下列重量份的原料药组成：苏合香1份；猪牙皂1.5份；前胡9份；十大功劳、大血藤20份;刺五加、蕨麻、广金钱草30份。
其中，苏合香：辛，温。归心、脾经。开窃，辟秽，止痛。苏合香具有显着的抗心肌缺血的效果，显著增加心肌梗塞患者的冠窦血流量，明显使其恢复正常或接近正常，并能明显减慢心率，明显降低心肌耗氧量，减慢心率和动-静脉压差。对于心肌缺血性超微结构改变有明显的保护效果，并能对抗心肌营养性血溶量的降低及去甲肾上腺素所致的主动脉收缩。
猪牙皂：辛、咸，温；有小毒。归肺、大肠经。祛痰开窍，散结消肿。注意孕妇及咯血、吐血患者禁用。明显对抗急性心肌缺血，明显减小心肌缺血时心肌梗死范围，且作用时间持久。
蕨麻：甘；苦；寒。归脾；胃经。补气血；健脾胃；生津止渴。蕨麻能显著降低缺血所致心电图J点的抬高, 减轻心肌超微结构损伤程度、减少缺血损伤心肌酶的释放, 明显减少心肌组织缺血面积，缺血所致肌纤维紊乱、线粒体膜和嵴融合、间质水肿等超微结构损伤均显著减轻，可显著降低缺血心肌组织蛋白表达。对缺血心率无明显影响。服用后,可显著提高血清中SOD活力,减少MDA的产生,并降低NO含量,升高NOS水平。提高机体清除自由基能力，阻断心肌细胞凋亡。
十大功劳:苦，寒。归肝；胃；肺；大肠经。根、茎有清热解毒、止咳化痰之功效。十大功劳改善更死后衰竭心室功能，使梗死范围减少，促使心肌功能恢复，延长心脏存活时间；能抑制血小板聚集；能显著减慢心率，增加心肌收缩力，降低心肌耗氧量，改善心功能。
大血藤：苦、涩，归大肠、肝经。清热解毒，活血，祛风。败毒消痈，活血通络，祛风杀虫。大血藤能使心肌梗塞已抬高的ST段显着下降，改善心肌乳酸代谢紊乱，并缩小心肌梗塞范围。
白花前胡：苦、辛，微寒。归肺经。散风清热，降气化痰。百花前胡能使左心室心肌梗死面积减小，改善高血压伴左心室肥厚所致左心室顺应性损害，改善心脏功能，增加心脏供血。对主动脉有一定的选择性扩血管作用，在增加心冠脉血流量的同时能显着降低血胆甾醇及血压，延缓心率、增强心收缩振幅、降低β/α脂蛋白比例，改善冠状循环。
广金钱草：甘、淡，凉。归肝、肾、膀胱经。清热除湿，利尿通淋。广金钱草总黄酮能明显抑制血栓形成，明显增加脑血流量和冠状动脉血流量，明显增加心肌营养性血流量, 对急性缺血有明显的保护作用。能显著增加耐缺氧能力，较强清除自由基。对常压缺氧耐受力有显著的增加作用,有缓解血管条痉挛的作用。
刺五加：辛、微苦，温。归脾、肾、心经。益气健脾，补肾安神。刺五加提取物明显抑制过氧化脂质产生，能减弱心肌缺血组织损害，促进表面细胞的再生和心肌梗塞区域的恢复。
本发明是由中国传统的中草药制成，根据中医辨证论治及现代医学的若干原则，以成分确定、功效明晰的天然提取物的有序配伍，组合成了治疗心肌梗塞的中药组合物。
本发明通过诸药配伍，达到明显增加冠状动脉血流量、改善心肌供血、修复损伤心肌细胞、缩小直至消除心肌梗死面积及增强心肌细胞活力等功效，治心肌梗塞效果显著，具有很好的临床推广价值。用本药方施治梗塞，每日一剂，水煎100-150ml，分成两份，早晚各一份服用，安全可靠无明显毒副反应，不伤脾胃，便于患者长期坚持服用，标本兼治，不易复发。
本发明的中药组合物药味数目少，原料易得，工艺简单，成本低，效率高，有利于制药企业进行药品生产、质量控制；产品价格低，易于被患者接受。
本发明治疗费用相对低廉，远远低于西医的治疗费用。
本发明还提供了一种由上述治疗 的中药组合物制成的口服制剂，所述口服制 剂包括口服液、片剂、胶囊剂、丸剂等，优选剂型为片剂和胶囊剂，一日一剂，分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如，将煎煮后的药液杀菌消毒后装袋，制成口服液；或者将煎煮后的药液进行浓缩，烘干后，加入医学上可接收的辅料，然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述，仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰，均落在本发明的保护范围内。
Claims (4)
1.一种治疗心肌梗塞的中药组合物，其特征在于，该中药组合物包括：：苏合香0.5～1份；猪牙皂1～1.5份；前胡4.5～9份；十大功劳、大血藤、10～20份;刺五加、蕨麻、广金钱草15～30份。
2.根据权利要求1所述的一种治疗心肌梗塞的中药，其特征是由下列重量份的原料药组成：苏合香1份；猪牙皂1.5份；前胡9份；十大功劳、大血藤20份;刺五加、蕨麻、广金钱草30份。
3.一种治疗心肌梗塞的口服制剂，其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗心肌梗塞的口服制剂，其特征是包括口服液、片剂、胶囊剂、丸剂，优选胶囊剂和片剂。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010464481.7A CN111514236A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗心肌梗死（塞）的中药组合物 |
| CN2020104644817 | 2020-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116115705A true CN116115705A (zh) | 2023-05-16 |
Family
ID=71907499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010464481.7A Pending CN111514236A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗心肌梗死（塞）的中药组合物 |
| CN202110531026.9A Pending CN116115705A (zh) | 2020-05-28 | 2021-05-16 | 一种治疗心肌梗塞的中药组合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010464481.7A Pending CN111514236A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗心肌梗死（塞）的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111514236A (zh) |
-
2020
- 2020-05-28 CN CN202010464481.7A patent/CN111514236A/zh active Pending
-
2021
- 2021-05-16 CN CN202110531026.9A patent/CN116115705A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111514236A (zh) | 2020-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101507765B (zh) | 一种用于治疗心脑血管疾病及其后遗症的药物及其制备方法 | |
| CN108524673A (zh) | 一种中药组合物及其应用 | |
| CN101422562A (zh) | 一种治疗早搏、房颤的药物 | |
| CN101152223B (zh) | 杨树叶酚类提取物在制备治疗心律失常的药物中的应用 | |
| CN116115705A (zh) | 一种治疗心肌梗塞的中药组合物 | |
| CN113144076A (zh) | 一种治疗心肌炎的中药组合物 | |
| CN102451340A (zh) | 一种治疗痛风的中药足浴方剂 | |
| CN111494512A (zh) | 一种治疗冠心症、心绞痛的中药组合物 | |
| CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
| CN106620253B (zh) | 一种治疗缓慢性心律失常的中药组合物 | |
| CN100430079C (zh) | 一种治疗心脏疾病的中药 | |
| CN103638428A (zh) | 一种治疗冠心病的中药组合物 | |
| CN101869689B (zh) | 治疗心绞痛型冠心病的外用中药组合物 | |
| CN115429836B (zh) | 一种用于治疗心律失常的中药制剂 | |
| CN113679781B (zh) | 一种治疗快速性心律失常的中药组合物及其制备方法和应用 | |
| CN111358888B (zh) | 一种用于治疗肺纤维化的中药组合物及其制备方法与用途 | |
| CN107260856A (zh) | 一种治疗乙肝的中药组合物及其制备方法 | |
| CN116077589A (zh) | 一种治疗老年性痴呆的中药组合物 | |
| CN111544470A (zh) | 一种治疗心力衰竭的中药组合物 | |
| CN105168653A (zh) | 一种用于治疗冠心病的中药组合物 | |
| CN111450183A (zh) | 一种治疗高血脂、动脉粥样硬化的中药组合物 | |
| CN104524313A (zh) | 一种治疗病态窦房结综合症的中药制剂 | |
| CN105055846A (zh) | 病态窦房结综合征及其治疗药物 | |
| CN105012746A (zh) | 一种治疗偏头痛的止痛胶囊及其制备方法 | |
| CN113893281A (zh) | 一种参芪降压丸及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230516 |
|
| WD01 | Invention patent application deemed withdrawn after publication |